Can protein, zinc, and hormones actually fix low libido in women?
Quick answer
The caption addresses female hypoactive sexual desire disorder (HSDD), particularly in the perimenopause context, and lists a range of interventions spanning dietary supplements, peptides, hormones, and pharmaceutical medications. Because the spoken transcript is incoherent and unverifiable, the clinical claims evaluated here are drawn entirely from the written caption. The category tag of TRT is relevant since off-label low-dose testosterone is among the better-evidenced options for libido in perimenopausal and postmenopausal women, though it remains unapproved by the FDA for this indication.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @drtazmd actually say?
The transcript captured from this video is largely incoherent, likely due to a transcription error or audio corruption. The readable portion says something like "Last night, we're gonna now hold me No more stuff." That is not a medical claim. So we are working primarily from the caption, which is a real medical claim in its own right.
The caption states that low libido in women "does not have to be this way" and pitches a "huge toolbox" including protein, zinc supplementation, peptides, hormones, and medications. That is a specific enough claim to fact-check, even if the spoken content is unverifiable from the transcript provided.
Does the science back this up?
Partially, yes. Low libido in women, particularly around perimenopause, is a well-documented clinical issue with real treatment options. But the "toolbox" framing oversimplifies a condition that is notoriously difficult to treat.
Hypoactive sexual desire disorder (HSDD) affects an estimated 10% of premenopausal women and higher rates in perimenopausal and postmenopausal populations (Shifren et al., 2008, Obstetrics and Gynecology). The FDA has approved exactly two medications for HSDD in premenopausal women: flibanserin (Addyi) and bremelanotide (Vyleesi). Neither has strong efficacy data. Flibanserin's clinical trials showed roughly 0.5 additional satisfying sexual events per month over placebo (Katz et al., 2013, Journal of Sexual Medicine). That is a modest benefit at best.
Low-dose testosterone is used off-label in women and has the most consistent evidence for improving libido in postmenopausal women (Davis et al., 2019, Lancet Diabetes and Endocrinology), though it is not FDA-approved for this indication. Zinc's role is real but limited. Peptides like PT-141 (bremelanotide) are in that toolbox too, though the compounded versions circulating on wellness platforms are not equivalent to the approved injectable.
What did they get wrong (or right)?
The core message, that women do not have to accept low libido and that options exist, is defensible. That part is right, and it addresses a real clinical gap where women are often dismissed.
What is less defensible is the framing that bundles protein, zinc, peptides, hormones, and medications as if they sit on the same shelf with similar evidence quality. They do not. Protein optimization and zinc have weak direct libido data. Zinc deficiency can suppress testosterone, but supplementing above sufficiency does not reliably boost libido (Prasad et al., 1996, Nutrition). Lumping this with FDA-approved medications or off-label testosterone therapy flattens a real hierarchy of evidence.
The peptide mention is worth flagging. "Peptides" in a wellness context often refers to compounded versions of agents like PT-141 or growth hormone secretagogues. These carry regulatory and safety questions that a TikTok caption is not going to resolve. Calling them part of a "toolbox" without that context is a shortcut that could steer women toward unvetted products.
What should you actually know?
Female sexual dysfunction is real medicine, not a lifestyle issue, and the evidence base is thinner than the wellness industry implies. Here is what actually holds up.
Testosterone therapy has the strongest evidence for libido in postmenopausal women, but it requires monitoring for androgenic side effects and is prescribed off-label in the US. Hormonal contraceptives can suppress libido in some women, and addressing that directly may matter more than adding supplements (Bancroft et al., 2003, Archives of Sexual Behavior). Psychosocial and relationship factors are significant contributors that no supplement addresses. A proper workup, thyroid function, prolactin levels, medication review, and depression screening, belongs before any "toolbox" discussion.
If a telehealth platform is offering this toolbox, ask specifically which interventions have FDA approval or peer-reviewed efficacy data for your specific situation. "Hormone balance" as a category is not a diagnosis.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 11 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Can protein, zinc, and hormones actually fix low libido in women?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Can protein, zinc, and hormones actually fix low libido in women? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The caption addresses female hypoactive sexual desire disorder (HSDD), particularly in the perimenopause context, and lists a range of interventions spanning dietary supplements, peptides, hormones, and pharmaceutical medications.
FormBlends verdict
The caption addresses female hypoactive sexual desire disorder (HSDD), particularly in the perimenopause context, and lists a range of interventions spanning dietary supplements, peptides, hormones, and pharmaceutical medications. Because the spoken transcript is incoherent and unverifiable, the clinical claims evaluated here are drawn entirely from the written caption. The category tag of TRT is relevant since off-label low-dose testosterone is among the better-evidenced options for libido in perimenopausal and postmenopausal women, though it remains unapproved by the FDA for this indication.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The caption addresses female hypoactive sexual desire disorder (HSDD), particularly in the perimenopause context, and lists a range of interventions spanning dietary supplements, peptides, hormones, and pharmaceutical medications. Because the spoken transcript is incoherent and unverifiable, the clinical claims evaluated here are drawn entirely from the written caption. The category tag of TRT is relevant since off-label low-dose testosterone is among the better-evidenced options for libido in perimenopausal and postmenopausal women, though it remains unapproved by the FDA for this indication.
- 2 medications are FDA-approved for female HSDD: flibanserin (Addyi) for premenopausal women and bremelanotide (Vyleesi), both with modest effect sizes in clinical trials.
- Off-label low-dose testosterone shows the most consistent libido benefit in postmenopausal women per a 2019 Lancet Diabetes and Endocrinology review by Davis et al., but is not FDA-approved for this use.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- 2 medications are FDA-approved for female HSDD: flibanserin (Addyi) for premenopausal women and bremelanotide (Vyleesi), both with modest effect sizes in clinical trials.
- Off-label low-dose testosterone shows the most consistent libido benefit in postmenopausal women per a 2019 Lancet Diabetes and Endocrinology review by Davis et al., but is not FDA-approved for this use.
- Zinc supplementation only addresses libido if a deficiency is present. Taking more zinc than you need does not reliably increase sexual desire.
- Compounded peptides are not the same as FDA-approved versions. Do not assume a compounded PT-141 or similar product carries the same safety profile as an approved drug.
- Hormonal contraceptives are an underrecognized cause of low libido. A medication review should happen before any supplementation protocol is started (Bancroft et al., 2003, Archives of Sexual Behavior).
- Perimenopause-related libido changes often involve multiple factors including estrogen decline, relationship dynamics, depression, and sleep disruption. No single supplement addresses all of these.
- The spoken transcript of this video was incoherent and could not be verified. The claims evaluated here come from the caption only, which is an important limitation of this fact-check.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Taz MD · TikTok creator
32.0K views on this video
Has this happened to you? So many women see me in my practices @CentreSpringMD and love their partners but have lost their libido. It does not have to be this way… There is a huge toolbox to boost libido - from protein to zinc supplementation to peptides, hormones and medications - don’t let a hormone shift steal your mojo… 😉 #libido #hormoneshifts #hormonebalance #nolibido #perimenopause
Sources & references
- [1]Shifren et al., 2008
- [2]Katz et al., 2013
- [3]Davis et al., 2019
- [4]Prasad et al., 1996
- [5]Bancroft et al., 2003
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Dr. Taz MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.